PBL
MCID: PLS025
MIFTS: 47

Plasmablastic Lymphoma (PBL)

Categories: Blood diseases, Immune diseases, Oral diseases, Rare diseases

Aliases & Classifications for Plasmablastic Lymphoma

MalaCards integrated aliases for Plasmablastic Lymphoma:

Name: Plasmablastic Lymphoma 52 58 71
Immunoblastic Large-Cell Lymphoma 71
Pbl 58

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

ICD10 via Orphanet 33 C83.3
UMLS via Orphanet 72 C3472614
Orphanet 58 ORPHA289666
UMLS 71 C0079746 C3472614

Summaries for Plasmablastic Lymphoma

NIH Rare Diseases : 52 Plasmablastic lymphoma is an aggressive form of non-Hodgkin lymphoma . Although the condition most commonly occurs in the oral cavity, it can be diagnosed in many other parts of the body such as the gastrointestinal tract, lymph nodes , and skin. The exact underlying cause of plasmablastic lymphoma is poorly understood; however, it is often associated with suppression of the immune system (i.e. HIV infection , immunosuppressive therapy). There is currently no standard therapy for plasmablastic lymphoma. Treatment usually consists of chemotherapy with or without radiation therapy and hematopoietic stem cell transplantation .

MalaCards based summary : Plasmablastic Lymphoma, also known as immunoblastic large-cell lymphoma, is related to lymphoma aids related and acquired immunodeficiency syndrome. An important gene associated with Plasmablastic Lymphoma is MYC (MYC Proto-Oncogene, BHLH Transcription Factor), and among its related pathways/superpathways are Gastric cancer and NF-kappaB Signaling. The drugs Orange and Ketamine have been mentioned in the context of this disorder. Affiliated tissues include b cells, bone and bone marrow, and related phenotypes are Reduced mammosphere formation and cardiovascular system

Wikipedia : 74 Plasmablastic lymphoma is a type of large B-cell lymphoma, recognized in the WHO 2008... more...

Related Diseases for Plasmablastic Lymphoma

Diseases related to Plasmablastic Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 291)
# Related Disease Score Top Affiliating Genes
1 lymphoma aids related 31.3 MYC BCL6
2 acquired immunodeficiency syndrome 31.0 MYC CD38 BCL6
3 lymphoma, hodgkin, classic 31.0 PTPRC MS4A1 BCL6
4 suppressor of tumorigenicity 3 30.8 MYC CDKN2A
5 b-cell non-hodgkin lymphoma 30.8 MS4A1 BCL6
6 lymphosarcoma 30.7 PTPRC BCL6
7 immune deficiency disease 30.6 VDR PTPRC CD38 BCL6
8 bone lymphoma 30.5 PTPRC BCL6
9 follicular lymphoma 30.3 MYC MS4A1 BCL6
10 lymphoma, mucosa-associated lymphoid type 30.2 PTPRC MYC BCL6
11 leukemia, chronic lymphocytic 2 30.2 MS4A1 CD38
12 richter's syndrome 30.2 NOTCH1 MYC CD38
13 b-cell lymphoma 29.9 PTPRC PRDM1 MYC MS4A1 CDKN2A BCL6
14 sarcoma 29.5 PTPRC MYC MUC1 MTOR ABCB1
15 plasmacytoma 29.5 PTPRC PRDM1 MYC CDKN2A CD38
16 lymphoma 29.4 PTPRC PRDM1 MYC MS4A1 CDKN2A CD38
17 diffuse large b-cell lymphoma 29.4 PTPRC PRDM1 MYC MTOR CDKN2A CD38
18 burkitt lymphoma 29.3 PRDM1 MYC MS4A1 CDKN2A BCL6
19 central nervous system lymphoma 29.3 PRDM1 MYC CDKN2A BCL6
20 squamous cell carcinoma 29.2 NOTCH1 MYC MUC1 CDKN2A
21 lymphocytic leukemia 29.1 PTPRC NOTCH1 MYC MS4A1 CD38 ABCB1
22 myelodysplastic syndrome 29.0 NOTCH1 MYC CDKN2A CD38 ABCB1
23 glioblastoma multiforme 28.7 NOTCH1 MYC MTOR CDKN2A ABCB1
24 rhabdomyosarcoma 28.7 PTPRC MYC MTOR DES CDKN2A ABCB1
25 acute promyelocytic leukemia 28.6 VDR PTPRC NOTCH1 MYC BCL6 ABCB1
26 inflammatory bowel disease 28.6 VDR PTPRC MYC MUC1 ABCB1
27 lung cancer susceptibility 3 28.5 NOTCH1 MYC MUC1 MTOR CDKN2A ABCB1
28 leukemia, chronic lymphocytic 28.4 PTPRC NOTCH1 MYC MS4A1 CDKN2A CD38
29 lymphoma, non-hodgkin, familial 27.9 PTPRC PRDM1 NOTCH1 MYC MTOR MS4A1
30 leukemia, acute myeloid 27.8 PTPRC NOTCH1 MYC MTOR CDKN2A CD38
31 mantle cell lymphoma 27.5 PTPRC PRDM1 NOTCH1 MYC MTOR MS4A1
32 myeloma, multiple 27.1 PTPRC PRDM1 NOTCH1 MYC MUC1 MTOR
33 caspase 8 deficiency 11.3
34 human herpesvirus 8 10.6
35 high grade b-cell lymphoma with myc and/ or bcl2 and/or bcl6 rearrangement 10.5 MYC BCL6
36 gallbladder signet ring cell adenocarcinoma 10.5 MYC MUC1
37 kaposi sarcoma 10.5
38 pancreas lymphoma 10.4 PTPRC BCL6
39 cerebral primitive neuroectodermal tumor 10.4 MYC MUC1
40 hodgkin's lymphoma, lymphocytic-histiocytic predominance 10.4 PTPRC BCL6
41 epiglottis neoplasm 10.4 PTPRC BCL6
42 heart lymphoma 10.4 PTPRC BCL6
43 human immunodeficiency virus type 1 10.4
44 lymphoproliferative syndrome 10.4
45 primary cutaneous anaplastic large cell lymphoma 10.4 PTPRC MUC1
46 pediatric lymphoma 10.4 MYC BCL6
47 primary cutaneous diffuse large b-cell lymphoma, leg type 10.4 MYC CDKN2A
48 malignant peritoneal mesothelioma 10.4 MUC1 CDKN2A
49 vulvar eccrine porocarcinoma 10.4 MUC1 CDKN2A
50 endometrial mucinous adenocarcinoma 10.4 MUC1 CDKN2A

Graphical network of the top 20 diseases related to Plasmablastic Lymphoma:



Diseases related to Plasmablastic Lymphoma

Symptoms & Phenotypes for Plasmablastic Lymphoma

GenomeRNAi Phenotypes related to Plasmablastic Lymphoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.1 BCL6 DES MTOR MYC NOTCH1 PTPRC

MGI Mouse Phenotypes related to Plasmablastic Lymphoma:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.21 ABCB1 BCL6 CDKN2A DES MTOR MYC
2 cellular MP:0005384 10.19 BCL6 CD38 CDKN2A DES MTOR MYC
3 endocrine/exocrine gland MP:0005379 10.16 ABCB1 BCL6 CD38 CDKN2A MTOR MYC
4 hematopoietic system MP:0005397 10.14 ABCB1 BCL6 CD38 CDKN2A MS4A1 MTOR
5 homeostasis/metabolism MP:0005376 10.11 ABCB1 BCL6 CD38 CDKN2A DES MTOR
6 growth/size/body region MP:0005378 10.09 ABCB1 BCL6 CDKN2A MTOR MYC NOTCH1
7 immune system MP:0005387 10.06 ABCB1 BCL6 CD38 CDKN2A MS4A1 MTOR
8 digestive/alimentary MP:0005381 9.95 ABCB1 CDKN2A MYC NOTCH1 PTPRC VDR
9 mortality/aging MP:0010768 9.85 ABCB1 BCL6 CDKN2A DES MTOR MYC
10 liver/biliary system MP:0005370 9.8 ABCB1 BCL6 CDKN2A MYC NOTCH1 PRDM1
11 muscle MP:0005369 9.56 BCL6 CDKN2A DES MTOR MYC NOTCH1
12 no phenotypic analysis MP:0003012 9.17 ABCB1 BCL6 CDKN2A MTOR MYC PRDM1

Drugs & Therapeutics for Plasmablastic Lymphoma

Drugs for Plasmablastic Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 385)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Orange Approved Phase 3
2
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
3
Etoposide Approved Phase 3 33419-42-0 36462
4
Idarubicin Approved Phase 3 58957-92-9 42890
5
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
6
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
7
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
8
Carmustine Approved, Investigational Phase 3 154-93-8 2578
9
Melphalan Approved Phase 3 148-82-3 4053 460612
10
Acyclovir Approved Phase 3 59277-89-3 2022
11
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
12
Aldesleukin Approved Phase 3 85898-30-2, 110942-02-4
13
Dalteparin Approved Phase 3 9005-49-6
14
Ofloxacin Approved Phase 3 82419-36-1 4583
15
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
16
Darbepoetin alfa Approved, Investigational Phase 3 11096-26-7, 209810-58-2
17
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
18
Tazobactam Approved Phase 3 89786-04-9 123630
19
Piperacillin Approved Phase 3 66258-76-2 43672
20
Vancomycin Approved Phase 3 1404-90-6 441141 14969
21
Caspofungin Approved Phase 3 179463-17-3, 162808-62-0 468682 2826718
22
Iodine Approved, Investigational Phase 3 7553-56-2 807
23
Morphine Approved, Investigational Phase 3 57-27-2 5288826
24
Captopril Approved Phase 3 62571-86-2 44093
25
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
26
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
27
Palivizumab Approved, Investigational Phase 3 188039-54-5
28
Ribavirin Approved Phase 3 36791-04-5 37542
29
Mercaptopurine Approved Phase 3 50-44-2 667490
30
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
31
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
32
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
33
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
34
Polyestradiol phosphate Approved Phase 3 28014-46-2
35
Moxifloxacin Approved, Investigational Phase 3 354812-41-2, 151096-09-2 152946
36
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
37
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
38
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
39
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
40
Glutamic acid Approved, Nutraceutical Phase 3 56-86-0 33032
41 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
42 Interferon alpha-2 Phase 3
43 Interferon-alpha Phase 3
44 Anesthetics, Dissociative Phase 3
45 Analgesics Phase 3
46 Topoisomerase Inhibitors Phase 3
47 Etoposide phosphate Phase 3
48 Antiviral Agents Phase 3
49 interferons Phase 3
50 Heparin, Low-Molecular-Weight Phase 3

Interventional clinical trials:

(show top 50) (show all 542)
# Name Status NCT ID Phase Drugs
1 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
2 A Randomised Study of High Dose Chemotherapy/Radiotherapy and Autologous Bone Marrow Transplantation in Patients With High Grade Malignant Non-Hodgkin's Lymphoma (Kiel Classification) According to Prognostic Groups Unknown status NCT00003815 Phase 3 carmustine;cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;melphalan;prednisolone;vincristine sulfate
3 A Randomized Phase III Study to Assess Intensification of the Conditioning Regimen for Allogenic Stem Cell Transplantation (ALLO-SCT) for Leukemia or Myelodysplastic Syndrome With a High Risk of Relapse Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
4 The Utility of LymphoScan Imaging in the Dectection of Residual Tumor After Chemotherapy and/or Radiotherapy in Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
5 The Utility of LymphoScan Imaging in the Localization and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
6 Randomised Trial Comparing Chemotherapy Mit CHOEP (Cyclophosphamid, Doxorubicin, Vincristin, Etoposid Und Prednison) In 21-Day Intervals In Standard And Escalated Doses In Patients Aged 18-60 Years Of Age With Aggresive Non-Hodgkin-Lymphomas Favourable Prognoses Unknown status NCT00053768 Phase 3 EPOCH regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
7 A Prospective Randomised Phase III Trial of Early Hospital Discharge Versus Standard Inpatient Management of Cancer Patients With Low-Risk Febrile Neutropenia Receiving Oral Antibiotics. Oral Antibiotics for Neutropenic Sepsis Giving Early Hospital Discharge [ORANGE] Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
8 Multicenter, Double-Blind, Randomized Study to Compare the Safety and Efficacy of Levofloxacin With That of Cefepime in the Treatment of Fever and Neutropenia - Phase IIIB Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
9 A Randomized Trial to Evaluate Early High Dose Therapy and Autologous Bone Marrow Transplantation as Part of Planned Initial Therapy for Poor Risk Intermediate/High Grade NHL Unknown status NCT00003578 Phase 3 CHOP regimen;carmustine;cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;melphalan;prednisone;vincristine sulfate
10 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
11 A European Randomized Multicenter Study of Interferon Alfa-2b Versus No Treatment After Intensive Therapy and Autologous Hematopoietic Stem Cell Transplantation for Relapsing Lymphoma Patients (Non-Hodgkin Lymphomas and Hodgkin's Disease) Unknown status NCT00003924 Phase 3
12 A RANDOMIZED PROSPECTIVE TRIAL OF CHOP VERSUS MCOP IN ELDERLY PATIENTS WITH INTERMEDIATE AND HIGH GRADE NON-HODGKIN'S LYMPHOMA (AGED 65 YEARS AND OVER) Completed NCT00002576 Phase 3 cyclophosphamide;doxorubicin hydrochloride;mitoxantrone hydrochloride;prednisolone;vincristine sulfate
13 RANDOMIZED COMPARISON OF ALTERNATING TRIPLE THERAPY ("ATT") VERUS CHOP IN PATIENTS WITH INTERMEDIATE GRADE LYMPHOMAS AND IMMUNOBLASTIC LYMPHOMAS WITH INTERNATIONAL INDEX 2-5 Completed NCT00002565 Phase 3 CHOP regimen;cisplatin;cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;idarubicin;ifosfamide;mesna;methylprednisolone;mitoxantrone hydrochloride;prednisone;vincristine sulfate
14 Phase III Trial Comparing CHOP ot PMitCEBO in Good Risk Patients With Histologically Aggresive Non Hodgkin's Lymphoma Completed NCT00005867 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;mitoxantrone hydrochloride;prednisolone;vincristine sulfate
15 Phase III Trial of CHOP Versus CHOP and Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2B8) in Older Patients With Diffuse Mixed, Diffuse Large Cell and Immunoblastic Large Cell Histology Non-Hodgkin's Lymphoma Completed NCT00003150 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
16 A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters Completed NCT00006083 Phase 3 Fragmin
17 A Randomized, Prospective Double-Blind, Placebo-Controlled Trial of Prophylactic Oral Levofloxacin Following Chemotherapy for Lymphoma and Solid Tumors Completed NCT00005590 Phase 3 levofloxacin
18 A Randomized, Open-Label, Multicenter Study Of Darbepoetin Alfa Administered Once Every Two Weeks (Q2W) Compared With rHuEPO Administered Once Every Week (QW) For The Treatment Of Anemia In Subjects With Non-Myeloid Malignancies Receiving Multiple Chemotherapy Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
19 Does Hypericum Reduce Fatigue in Cancer Patients on Chemotherapy? A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Completed NCT00005805 Phase 3
20 Vancomycin Versus Placebo in Persistently Febrile Granulocytopenic Patients Given Piperacillin/Tazobactam Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
21 A Randomized Prospective Study of Early Intensification Versus Alternating Triple Therapy for Patients With Poor Prognosis Lymphoma Completed NCT00002835 Phase 3 Carmustine;Cisplatin (CDDP);Cyclophosphamide;Cytarabine (ARA-C);Etoposide (VP-16);Idarubicin;Ifosfamide;Leucovorin Calcium;Melphalan;Methotrexate;Methylprednisolone;mitoxantrone hydrochloride (DHAD);Vincristine Sulfate
22 The Effects of Procrit (Epoetin Alfa) on Hemoglobin Symptom Distress and Quality of Life During Chemotherapy in Lymphoma Patients With Mild to Moderate Anemia A Multicenter Trial Completed NCT00003341 Phase 3
23 Standard Chemotherapy (CHOP Regimen) Versus Sequential High-Dose Chemotherapy With Autologous Stem Cell Transplantation in Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas and Poor Prognostic Factors: A Randomized Phase III Study (MISTRAL) Completed NCT00003215 Phase 3 CHOP regimen;cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;leucovorin calcium;melphalan;methotrexate;methylprednisolone;mitoxantrone hydrochloride;prednisone;therapeutic hydrocortisone;vincristine sulfate
24 Randomized Study Comparing 4 and 6 Cycles of Chemotherapy With CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) at 21-day Intervals, Both With 6 Cycles of Immunotherapy With the Monoclonal Anti-CD20-Positive B-Cell Lymphoma Aged 18-60 Years Having no Risk Factor (Age-Adjusted IPI=0) and No Large Tumor Mass (Diameter <7,5cm) [FLYER 6-6-6-4 Study] Completed NCT00278421 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
25 A Double-Blind Study Of Nutritional Intervention For The Treatment Of Cancer Cachexia Using Juven® Nutritional Supplement Completed NCT00053053 Phase 3
26 A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Cancer Patients With Chemotherapy-Associated Anemia Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
27 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
28 Phase III Study of Captopril in Patients Undergoing Autologous Bone Marrow/Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
29 SWOG-9704 A Randomized Phase III Trial Comparing Early High Dose Chemoradiotherapy and an Autologous Stem Cell Transplant to Conventional Dose CHOP Chemotherapy Plus Rituximab for CD20+ B Cell Lymphomas (With Possible Late Autologous Stem Cell Transplant) for Patients With Diffuse Aggressive Non-Hodgkin's Lymphoma in the High-Intermediate and High Risk International Classification Prognostic Groups Completed NCT00004031 Phase 3 CHOP regimen;carmustine;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
30 A Randomized, Comparative Study of Itraconazole Versus Fluconazole for Prevention of Aspergillus Infections in Peripheral Blood Stem Cell and Marrow Transplant Recipients Completed NCT00003883 Phase 3 fluconazole;itraconazole
31 A Randomized Double-Blind Placebo-Controlled Phase III Study To Evaluate The Safety And Efficacy Of Palivizumab Combined With Aerosolized Ribavirin Compared To Ribavirin Alone To Treat RSV Pneumonia In Patients With Bone Marrow Transplants (BMT) Completed NCT00014391 Phase 3 ribavirin
32 Music Video and Adolescent/Young Adult Resilience During Transplant Completed NCT00305851 Phase 3
33 A Phase III Multicenter Study of Cytomegalovirus Prophylaxis With Valacyclovir for the Prevention of Serious Fungal and Bacterial Infections Among Cytomegalovirus Seronegative Recipients of Cytomegalovirus Seropositive Sx Stem Cell Transplants Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
34 Randomized Study Comparing an Immuno-Chemotherapy With 6 Cycles of the Monoclonal Anti-CD20 Antibody Rituximab in Combination With 6 Cycles of Chemotherapy With CHOP ( Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) at 21-day Intervals or 14-day Intervals, Both With or Without Consolidating Radiotherapy or Large Tumour Masses (≥7.5 cm) and/or Extranodal Involvement in Patients With Aggressive CD20 B-Cell Lymphoma Aged 18 to 60 Years With Age-Adjusted IPI=1 (All) or IPI=0 With a Large Tumour Mass (≥7.5 cm) [UNFOLDER 21/14 Study] Completed NCT00278408 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
35 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
36 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
37 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
38 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
39 A Phase III Study of Large Cell Lymphomas in Children and Adolescents: Comparison of APO vs APO + IDMTX/HDARA-C and Continuous vs Bolus Infusion of Doxorubicin Completed NCT00002618 Phase 3 cytarabine;doxorubicin hydrochloride;leucovorin calcium;mercaptopurine;methotrexate;prednisone;vincristine sulfate
40 A Randomized Multicentre Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation for Hematologic Malignancies Completed NCT00438958 Phase 3
41 Randomized Placebo Controlled Double Blind Study of Restasis Versus Placebo in Primary Prevention of Ocular GVHD After Allogeneic Stem Cell Transplantation Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
42 A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
43 Phase III Trial of T Lymphocyte Depletion by Elutriation and CD34 Add-Back for Allogeneic Bone Marrow Transplantation Completed NCT00265837 Phase 3
44 Randomized Trial of Autologous GVHD for Refractory Lymphoma Completed NCT00003414 Phase 3 busulfan;cyclophosphamide;cyclosporine
45 Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer Completed NCT00006348 Phase 3 ondansetron
46 Randomized Trial of CHOP Chemotherapy With or Without Rituximab (Chimeric Anti-CD20 Antibody) for HIV-Associated Non-Hodgkin's Lymphoma Completed NCT00003595 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
47 Glutamic Acid to Decrease Vincristine Toxicity in Children With Cancer Completed NCT00369564 Phase 3 glutamic acid
48 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
49 Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia Completed NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
50 Total Body Irradiation, Etoposide, Cyclophosphamide and Autologous Peripheral Blood Stem Cell Transplantation Followed by Randomization to Therapy With Interleukin-2 Versus Observation for Patients With Non-Hodgkin's Lymphoma Completed NCT00002649 Phase 3 cyclophosphamide;etoposide

Search NIH Clinical Center for Plasmablastic Lymphoma

Genetic Tests for Plasmablastic Lymphoma

Anatomical Context for Plasmablastic Lymphoma

MalaCards organs/tissues related to Plasmablastic Lymphoma:

40
B Cells, Bone, Bone Marrow, T Cells, Skin, Liver, Lymph Node

Publications for Plasmablastic Lymphoma

Articles related to Plasmablastic Lymphoma:

(show top 50) (show all 541)
# Title Authors PMID Year
1
High incidence of MYC rearrangement in human immunodeficiency virus-positive plasmablastic lymphoma. 61
31348551 2020
2
Extraoral plasmablastic lymphomas in a high human immunodeficiency virus endemic area. 61
31361906 2020
3
Axicabtagene ciloleucel for CD19+ plasmablastic lymphoma. 61
31725923 2020
4
Plasmablastic lymphoma achieving sustained remission with antiretroviral therapy alone. 61
31505061 2019
5
Lymphoid neoplasms of the oral cavity with plasmablastic morphology-a case series and review of the literature. 61
31494113 2019
6
Bortezomib- and Lenalidomide-Based Treatment of Refractory Plasmablastic Lymphoma. 61
31842017 2019
7
Diffuse large B-cell lymphoma variants: an update. 61
31735345 2019
8
Diverse clinical and histopathologic features of cutaneous post-transplant lymphoproliferative disorders: A presentation of two cases. 61
31144292 2019
9
Non- Hodgkin lymphoma of the lips: A rare entity. 61
31570207 2019
10
Lymphoid Neoplasms With Plasmablastic Differentiation: A Comprehensive Review and Diagnostic Approaches. 61
31725418 2019
11
Plasmablastic lymphoma of the maxillary sinus. 61
31522367 2019
12
Therapeutic Potential of Checkpoint Inhibitors in Refractory Plasmablastic Lymphoma. 61
31377210 2019
13
Plasmablastic lymphoma of the rectum, a rare cause of lower gastrointestinal bleeding: A case report. 61
30665721 2019
14
Breast Implant-associated Plasmablastic Lymphoma: A Case Report and Discussion of the Literature. 61
31383476 2019
15
EBV positive mucocutaneous ulcer with plasmacytic/plasmablastic differentiation and MYC rearrangement: a diagnostic challenge and a mimic of plasmablastic lymphoma. 61
31472984 2019
16
Autologous stem cell transplantation for HIV-associated lymphoma in the antiretroviral and rituximab era: a retrospective study by the EBMT Lymphoma Working Party. 61
30804486 2019
17
Large B cell lymphoma of the Uvea: Histopathologic Variants and Clinico-Pathologic Correlation. 61
31676312 2019
18
Oral lesion as the primary diagnosis of non-Hodgkin's lymphoma: a 20-year experience from an oral pathology service and review of the literature. 61
31286184 2019
19
Navigating the cutaneous B-cell lymphomas: avoiding the rocky shoals. 61
31653979 2019
20
A retrospective review of cutaneous lymphoma in Botswana. 61
31647120 2019
21
Fifty Shades of GATA2 Mutation: A Case of Plasmablastic Lymphoma, Nontuberculous Mycobacterial Infection, and Myelodysplastic Syndrome. 61
31279773 2019
22
HIV/AIDS-related lymphoma: perspective from a regional cancer center in India. 61
31730692 2019
23
Spontaneous regression of a plasmablastic lymphoma with MYC rearrangement. 61
31257571 2019
24
Incorporating Bortezomib in the Management of Plasmablastic Lymphoma. 61
31519607 2019
25
Blastic variant of plasma cell myeloma mimicking squamous cell carcinoma of the uterine cervix in a super-morbidly obese female. 61
31249854 2019
26
Cutaneous localization of plasmablastic multiple myeloma with heterotopic expression of CD3 and CD4: Skin involvement revealing systemic disease. 61
31025408 2019
27
CD-20 Negative Plasmablastic Lymphoma Lurking in the Shadow of a Leiomyoma - Diagnosis and Management. 61
31565620 2019
28
Plasmablastic Lymphoma Versus EBV-Positive Myeloma. 61
31388277 2019
29
Plasmablastic Lymphoma of the Nasal Septum. 61
31318382 2019
30
Plasmablastic lymphoma presenting as a brachial artery aneurysm associated with haemodialysis arteriovenous access ligation in a renal transplant patient. 61
31244374 2019
31
A Unique Case of Testicular Plasmablastic Lymphoma in a Patient with Human Immunodeficiency Virus. 61
31410322 2019
32
Follicular lymphoma suggested to transform into EBV-negative plasmablastic lymphoma. 61
30859398 2019
33
Clinicopathologic features, management, and outcomes of plasmablastic lymphoma: A 10-year experience. 61
30734351 2019
34
SLAMF7 (CD319/CS1) is expressed in plasmablastic lymphoma and is a potential diagnostic marker and therapeutic target. 61
29785767 2019
35
Solitary Primary Central Nervous System Plasmablastic Lymphoma in a Young Immunocompetent Female: Report on an Extremely Rare Entity with Review of Literature. 61
31143278 2019
36
Highly aggressive plasmablastic neoplasms in patients with rheumatoid arthritis treated with methotrexate. 61
30658314 2019
37
Primary central nervous system plasmablastic lymphoma in an HIV-positive patient. 61
30872336 2019
38
[Intestinal intussusception in adults, atypical and potentially dramatic]. 61
30793557 2019
39
Plasmablastic lymphoma presenting with ileocecal intussusception in an immunocompetent patient. 61
30808128 2019
40
Aggressive B cell lymphomas in the 2017 revised WHO classification of tumors of hematopoietic and lymphoid tissues. 61
30380402 2019
41
Epstein-Barr Virus-Positive CD20- and CD45-Negative Diffuse Large B-Cell Lymphoma: A Diagnostic Challenge. 61
29968492 2019
42
Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma. 61
29527667 2019
43
Severe Type B Lactic Acidosis in a Rare and Aggressive HIV-Related Lymphoma. 61
31531244 2019
44
A Rare Presentation of HIV-Negative Plasmablastic Lymphoma: A Diagnostic Dilemma. 61
30906602 2019
45
Plasmablastic Lymphoma, a Rare Entity in Bone Marrow with Unusual Immunophenotype and Challenging Differential Diagnosis. 61
31565447 2019
46
Plasmablastic lymphoma of bone marrow: Report of a rare case and immunohistochemistry based approach to the diagnosis. 61
30706870 2019
47
Epstein-Barr Virus Primary Infection Complicated by Hemophagocytic Lymphohistiocytosis and Plasmablastic Lymphoma in a HIV-Negative Patient. 61
31687232 2019
48
The Global Landscape of EBV-Associated Tumors. 61
31448229 2019
49
An Endotracheal Plasmablastic Lymphoma. 61
31634891 2019
50
HIV-associated lymphoma: A 5-year clinicopathologic study from India. 61
30706863 2019

Variations for Plasmablastic Lymphoma

Expression for Plasmablastic Lymphoma

Search GEO for disease gene expression data for Plasmablastic Lymphoma.

Pathways for Plasmablastic Lymphoma

Pathways related to Plasmablastic Lymphoma according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.32 NOTCH1 MYC MTOR CDKN2A ABCB1
2 12.25 PTPRC PRDM1 CD38 BCL6
3
Show member pathways
12.21 NOTCH1 MYC MTOR BCL6
4 12.05 NOTCH1 MYC MTOR CDKN2A ABCB1
5 11.96 MYC MTOR CDKN2A
6 11.85 VDR PRDM1 BCL6
7 11.79 NOTCH1 MYC MTOR
8 11.73 MYC CDKN2A BCL6
9 11.71 MYC MUC1 BCL6
10 11.68 MYC MTOR CDKN2A
11 11.41 PTPRC MS4A1 CD38
12
Show member pathways
11.36 PRDM1 MTOR CDKN2A
13 11.32 PTPRC NOTCH1 MS4A1 CD38
14
Show member pathways
10.92 MYC CDKN2A
15 10.91 MYC CDKN2A
16 10.78 VDR ABCB1
17 10.75 PTPRC PRDM1 MS4A1 CD38 BCL6
18 10.7 MTOR ABCB1
19 10.69 VDR ABCB1

GO Terms for Plasmablastic Lymphoma

Cellular components related to Plasmablastic Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.7 VDR PRDM1 NOTCH1 MYC MUC1 MTOR
2 cell surface GO:0009986 9.02 PTPRC NOTCH1 MS4A1 CD38 ABCB1

Biological processes related to Plasmablastic Lymphoma according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription by RNA polymerase II GO:0000122 9.88 VDR PRDM1 NOTCH1 MYC BCL6
2 negative regulation of cell proliferation GO:0008285 9.81 VDR NOTCH1 CDKN2A BCL6
3 negative regulation of transcription, DNA-templated GO:0045892 9.65 VDR NOTCH1 CDKN2A CD38 BCL6
4 B cell receptor signaling pathway GO:0050853 9.63 PTPRC MS4A1 CD38
5 B cell differentiation GO:0030183 9.5 PTPRC MS4A1 BCL6
6 negative regulation of cell-matrix adhesion GO:0001953 9.49 CDKN2A BCL6
7 positive regulation of keratinocyte differentiation GO:0045618 9.43 VDR NOTCH1
8 energy reserve metabolic process GO:0006112 9.4 MYC MTOR
9 somatic stem cell division GO:0048103 9.37 NOTCH1 CDKN2A
10 positive regulation of B cell proliferation GO:0030890 9.33 PTPRC CD38 BCL6
11 cell cycle arrest GO:0007050 9.26 NOTCH1 MYC MTOR CDKN2A
12 positive regulation of gene expression GO:0010628 9.1 VDR PRDM1 NOTCH1 MYC MTOR CDKN2A

Molecular functions related to Plasmablastic Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA-binding transcription factor activity GO:0003700 9.35 VDR PRDM1 NOTCH1 MYC BCL6
2 chromatin DNA binding GO:0031490 8.8 PRDM1 NOTCH1 BCL6

Sources for Plasmablastic Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....